Taking certain good bacteria supplements may slightly lower blood sugar and HbA1c in people with type 2 diabetes, but the effect isn't the same for everyone and depends on the type and amount of bacteria taken.
Scientific Claim
Probiotic supplementation in adults with type 2 diabetes is associated with modest reductions in fasting blood glucose and HbA1c levels, with meta-analyses reporting average decreases of approximately 13 mg/dL and 0.4–0.8%, respectively, though effects vary by strain, dose, and duration.
Original Statement
“A meta-analysis of 30 RCTs (1827 patients) showed that probiotics had a clear improvement in glycemic control in T2DM: fasting glucose, HbA1c, insulin, and HOMA-IR all reduced compared to placebo. Another review (28 RCTs) showed probiotics reduced fasting glucose by ≈13 mg/dL.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study reports meta-analytic findings from RCTs, which can support association. It avoids causal language like 'causes' and explicitly notes heterogeneity, aligning with the evidence level.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceWhether specific probiotic strains or combinations consistently reduce HbA1c and fasting glucose in T2DM across diverse populations.
Whether specific probiotic strains or combinations consistently reduce HbA1c and fasting glucose in T2DM across diverse populations.
What This Would Prove
Whether specific probiotic strains or combinations consistently reduce HbA1c and fasting glucose in T2DM across diverse populations.
Ideal Study Design
A pre-registered systematic review and meta-analysis of 40+ RCTs with standardized probiotic formulations (strain, dose, duration), stratified by metformin use, baseline HbA1c, and microbiome profile, measuring HbA1c and fasting glucose as primary endpoints.
Limitation: Cannot determine if effects are clinically meaningful or sustained beyond 12 months.
Randomized Controlled TrialLevel 1bIn EvidenceWhether a specific probiotic formulation (e.g., L. acidophilus La5 + B. lactis Bb12) reduces HbA1c by ≥0.5% compared to placebo in T2DM patients on stable metformin.
Whether a specific probiotic formulation (e.g., L. acidophilus La5 + B. lactis Bb12) reduces HbA1c by ≥0.5% compared to placebo in T2DM patients on stable metformin.
What This Would Prove
Whether a specific probiotic formulation (e.g., L. acidophilus La5 + B. lactis Bb12) reduces HbA1c by ≥0.5% compared to placebo in T2DM patients on stable metformin.
Ideal Study Design
A double-blind, placebo-controlled RCT of 200 adults with T2DM on stable metformin, randomized to 300g/day probiotic yogurt (L. acidophilus La5 + B. lactis Bb12, 10^10 CFU) or placebo for 24 weeks, with HbA1c as primary endpoint.
Limitation: Limited generalizability to other strains, doses, or populations not on metformin.
Prospective Cohort StudyLevel 2bIn EvidenceWhether long-term probiotic use is associated with reduced risk of T2DM progression or complications.
Whether long-term probiotic use is associated with reduced risk of T2DM progression or complications.
What This Would Prove
Whether long-term probiotic use is associated with reduced risk of T2DM progression or complications.
Ideal Study Design
A prospective cohort of 5,000 adults with prediabetes or early T2DM tracking probiotic use (dose, duration, strain) over 5 years, with HbA1c trajectory and microvascular complications as outcomes.
Limitation: Cannot control for confounding by diet, adherence, or socioeconomic factors.
Evidence from Studies
Supporting (1)
Modulating the Gut Microbiome in Type 2 Diabetes: Nutritional and Therapeutic Strategies
This study looked at multiple human trials and says probiotics might help lower blood sugar in people with type 2 diabetes, which matches what the claim says — but it doesn’t give exact numbers, so it’s not the strongest proof.